Is vascular endothelial growth factor a missing link between hypertension and inflammation?
Morishita
Ryuichi
R
D000804:Angiotensin II / Q000502:physiology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016326:Extracellular Matrix Proteins / Q000235:genetics / Q000502:physiology; D005804:Genes, Lethal; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000503:physiopathology / Q000517:prevention & control; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D018482:Muscle, Skeletal / Q000378:metabolism; D018995:Myosin Heavy Chains; D024501:Nonmuscle Myosin Type IIB; D051381:Rats; D014162:Transfection; D019076:Transgenes; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
D000893:Anti-Inflammatory Agents; D016326:Extracellular Matrix Proteins; D042461:Vascular Endothelial Growth Factor A; D000804:Angiotensin II; D024501:Nonmuscle Myosin Type IIB; C103815:nonmuscle myosin type IIB heavy chain; D018995:Myosin Heavy Chains